The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSt. Ives PLC Regulatory News (SIV)

Share Price Information for St. Ives PLC (SIV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 5.00 (20.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 27.50
SIV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RTO Transaction and Suspension of Listing

7 Dec 2021 08:23

RNS Number : 8151U
Sivota PLC
07 December 2021
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.  UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Sivota plc

("Sivota" or the "Company")

Reverse Takeover Transaction and Suspension of Listing

Conditional Acquisition of a controlling interest in Apester Limited 

Sivota ( LSE:SIV ), the investment company established for the purpose of undertaking acquisitions of a controlling stake in later stage Israeli-related technology companies, is pleased to announce that the Company has entered into a non-binding term sheet (the "Term Sheet") with Apester Limited ("Apester"), an Israeli incorporated business which operates an innovative digital experience software platform that enables brands, publishers and e-commerce to create and distribute interactive digital experiences.

Pursuant to the Term Sheet Sivota has conditionally agreed to be issued new preferred shares in the capital of Apester for a consideration of $12,000,000 (the "Transaction"). The Company will own c.53.9% of Apester's issued share capital on completion of the Transaction.

Pursuant to the Term Sheet, the Company will have certain major investor rights, including the right to appoint a majority of directors to the Apester Board, which it currently intends to exercise following completion.

The Transaction is subject to the satisfaction of certain conditions precedent, including the entry into the definitive transaction documentation and passing at a General Meeting of the Company of such resolutions necessary to approve, implement and effect the transaction.

 

Conditional, inter alia, on publication of a prospectus and re-admission, in order to fund the Transaction (including associated costs) the Company intends to raise c.£11,000,000 through the issue of new ordinary shares (the "Placing"). As such, the transaction is conditional, inter alia, on a successful Placing.

The Directors of Sivota consider the Transaction to represent a value enhancing transaction for shareholders, which is fully aligned with the Company's investment strategy. The Directors of Sivota believe that they can assist Apester in driving forward its SaaS revenue model and, by doing this, significantly enhancing value for both Sivota and Apester shareholders.

Should the Transaction complete, it would constitute a Reverse Take Over ("RTO") under the Listing Rules and accordingly, the Company would apply for the re-admission of its shares to the Official List and the Main Market of the London Stock Exchange.

 

Therefore, at the request of the Company, the FCA has suspended the Company's listing on the standard segment of the Official List and trading on the Main Market of the London Stock Exchange has also been suspended as of 7.30am today, pending the publication of a prospectus providing further detail on Apester and the Company as enlarged by the Transaction, or an announcement that the Transaction or RTO is not proceeding. Should the RTO not proceed, then the Company would need to apply for the suspension to be lifted and for trading to be restored.

There can be no certainty that the Transaction will proceed and it remains subject to, amongst other things, entering into a definitive legal agreement and obtaining all other necessary approvals (if required).

A further announcement will be made in due course.

 

 Enquiries:

Sivota PLC

Tim Weller, Non-Executive Chairman

Ziv Ben-Barouch, Chief Executive Officer

 

via Vigo Consulting

Canaccord Genuity Limited

Alex Aylen - Head of Equities

+ 44 (0) 20 7523 8000

Vigo Consulting

Jeremy Garcia / Antonia Pollock

+ 44 (0)20 7390 0230

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUBUWRAAUURRA
Date   Source Headline
26th Jan 20249:00 amRNSAppointment of Auditor
12th Jan 20247:00 amRNSEntry into non-binding term sheet
27th Sep 20239:42 amRNSHalf Year Results
7th Sep 20232:16 pmRNSResults of General Meeting
15th Aug 20237:30 amRNSNotice of General Meeting
8th Aug 20237:00 amRNSAppointment of CEO at Sivota’s subsidiary, Apester
21st Jun 20236:26 pmRNSResult of Annual General Meeting
26th May 20237:00 amRNSNotice of 2023 Annual General Meeting
22nd May 202311:16 amRNSChange of Registered Office
28th Apr 20231:52 pmRNSFinal Results
11th Jan 20237:00 amRNSBusiness update
22nd Nov 20221:17 pmRNSHolding(s) in Company
15th Nov 20229:25 amRNSHolding(s) in Company
14th Nov 20222:34 pmRNSHolding(s) in Company
14th Nov 20222:33 pmRNSHolding(s) in Company
14th Nov 20222:32 pmRNSHolding(s) in Company
14th Nov 20222:31 pmRNSHolding(s) in Company
14th Nov 20222:30 pmRNSHolding(s) in Company
14th Nov 20222:29 pmRNSHolding(s) in Company
30th Sep 20227:00 amRNSHalf-year Results
26th Sep 20228:00 amRNSReadmission - Sivota plc
26th Sep 20227:10 amRNSAppointment of CEO at Sivota’s subsidiary, Apester
26th Sep 20227:00 amRNSReadmission
22nd Sep 20222:38 pmRNSReadmission and Publication of Prospectus
22nd Sep 20227:00 amRNSReadmission and Publication of Prospectus
30th Aug 20222:24 pmRNSResult of AGM
17th Aug 20225:42 pmRNSNotice of AGM
30th Jun 20227:00 amRNSFinal Results
13th May 20227:00 amRNSAcquisition of Majority Stake in Apester & Placing
22nd Feb 20227:00 amRNSResults of General Meeting
28th Jan 20227:00 amRNSPosting of Shareholder Circular and Notice of GM
25th Jan 20227:00 amRNSConditional Acquisition of Stake in Apester
7th Dec 20218:23 amRNSRTO Transaction and Suspension of Listing
27th Sep 20218:40 amRNSHalf-year Results
5th Aug 20219:31 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.